drugset / Trial / NCT04074343
TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Phase 1
Completed
20 enrolled
University of California, Irvine
Taiho Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase Ib single-arm, open-label clinical trial determining the feasibility and efficacy of TAS-102 and irinotecan in subjects with advanced gastric and gastroesophageal adenocarcinoma. These are subjects who are not candidates for curative treatments and who have received at least one prior line of chemotherapy with a fluoropyrimidine and platinum agent.
Timeline
- Start
- 2019-08-26
- Primary completion
- 2021-07-14
- Completion
- 2022-07-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 180 mg/m2 | Intravenous |
| Subject | TAS-102 | Small molecule | 25 mg/m2 | Oral |